Determinants of Natural Killer Cell Ly49 Receptor Specificity

自然杀伤细胞 Ly49 受体特异性的决定因素

基本信息

  • 批准号:
    RGPIN-2016-03744
  • 负责人:
  • 金额:
    $ 2.26万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Discovery Grants Program - Individual
  • 财政年份:
    2016
  • 资助国家:
    加拿大
  • 起止时间:
    2016-01-01 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

Natural killer (NK) cells are lymphocytes that act as a first line of defense against viruses and tumours, destroying pathologically altered cells. NK cells express inhibitory receptors specific for class I (CI) major histocompatiblity complex molecules ubiquitously expressed on healthy cells. Lack of engagement of NK inhibitory receptors, due to loss of CI expression that typically occurs with virus-infected cells or tumour cells, releases inhibition of NK cells, allowing them to destroy such altered cells. Ly49 are large families of major class of CI-specific receptors expressed by mouse and rat NK cells, but not humans. CI associate with beta-2 microglobulin (b2m) and bind and present peptide fragments from intracellular proteolytic events. We, and others, have found that the identity of the CI-bound peptide can determine Ly49 recognition of CI. What is unclear, is the nature of endogenous peptides in healthy cells that regulate NK cells, and the in vivo significance of peptide selectivity by Ly49. Our long-term goal is to understand the molecular basis of peptide selectivity of Ly49 recognition. The significance and uniqueness of this undertaking is that it directly addresses the very fundamental biological question of the molecular basis of healthy cell recognition by NK cells. Furthermore, understanding Ly49 recognition, may provide novel insights into host resistance to infections such as hanta viruses in mice, and possibly diseases in horses, a species which also has an expanded Ly49 gene family. We hypothesize that certain and specific endogenous peptides support CI recognition by Ly49, identification of which will provide a window into the purpose of Ly49 surveillance. We also hypothesize that peptide selectivity determines Ly49 affinity thresholds, and has in vivo significance. To test these hypotheses, we propose the following objectives: 1. Assess diversity and identity of endogenous peptides controlling Ly49C recognition. Advances in mass spectrometry have identified endogenous peptides bound to CI. We will examine individual endogenous peptides bound to CI (Kb) in supporting Ly49C recognition, including their molecular properties and proteins of origin (from peptide sequence database matching), in contributing to the control of Ly49C recognition. 2. Define the influence of CI bound peptide identity in determining Ly49 affinity. We will determine the affinities of Ly49C for different CI (Kb)-peptide complexes by surface plasmon resonance. This should reveal whether there are threshold affinities for Ly49C interaction controlled by identities of bound peptides. 3. Determine the influence of Ly49 peptide selectivity on NK cell activity in vivo. By transgenesis on a b2m-/- background we will express genetically engineered single chain peptide-CI complexes to determine the ability of distinct individual peptides to support licensing and function of NK cells in vivo.
自然杀伤(NK)细胞是淋巴细胞,作为抵御病毒和肿瘤的第一道防线,摧毁病理改变的细胞。NK细胞表达对I类(CI)主要组织相容性复合物分子特异性的抑制性受体,其在健康细胞上普遍表达。由于通常在病毒感染的细胞或肿瘤细胞中发生的Cl表达的丧失,NK抑制性受体的参与的缺乏释放NK细胞的抑制,允许它们破坏这种改变的细胞。Ly 49是由小鼠和大鼠NK细胞表达的CI特异性受体的主要类别的大家族,但不是人类。CI与β-2微球蛋白(b2 m)结合,并结合和呈递来自细胞内蛋白水解事件的肽片段。我们和其他人已经发现,CI结合肽的身份可以决定Ly 49对CI的识别。目前尚不清楚的是健康细胞中调节NK细胞的内源性肽的性质,以及Ly 49对肽选择性的体内意义。我们的长期目标是了解Ly 49识别的肽选择性的分子基础。这项工作的重要性和独特性在于,它直接解决了NK细胞识别健康细胞的分子基础这一非常基本的生物学问题。此外,了解Ly 49的识别,可能会提供新的见解宿主抗感染,如汉坦病毒在小鼠中,并可能在马,一个物种,也有一个扩展的Ly 49基因家族的疾病。我们假设某些特定的内源性肽支持Ly 49对CI的识别,这将为Ly 49监测的目的提供一个窗口。我们还假设,肽的选择性决定Ly 49的亲和力阈值,并在体内的意义。为了检验这些假设,我们提出了以下目标: 1.评估控制Ly 49 C识别的内源性肽的多样性和同一性。质谱法的进展已经鉴定了与Cl结合的内源性肽。我们将研究与CI(Kb)结合的单个内源性肽,以支持Ly 49 C识别,包括它们的分子特性和起源蛋白(来自肽序列数据库匹配),有助于控制Ly 49 C识别。 2.定义Cl结合肽同一性在确定Ly 49亲和力中的影响。我们将通过表面等离子体共振测定Ly 49 C对不同Cl(Kb)-肽复合物的亲和力。这应该揭示是否存在由结合肽的身份控制的Ly 49 C相互作用的阈值亲和力。 3.确定Ly 49肽选择性对体内NK细胞活性的影响。通过在b2 m-/-背景上的转基因,我们将表达基因工程改造的单链肽-Cl复合物以确定不同的单个肽支持体内NK细胞的许可和功能的能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kane, Kevin其他文献

Microvascular changes in Down syndrome with Alzheimer's-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease
  • DOI:
    10.1016/j.jalz.2017.05.003
  • 发表时间:
    2017-12-01
  • 期刊:
  • 影响因子:
    14
  • 作者:
    Drachman, David A.;Smith, Thomas W.;Kane, Kevin
  • 通讯作者:
    Kane, Kevin
The Healthy Kids & Families study: Outcomes of a 24-month childhood obesity prevention intervention.
  • DOI:
    10.1016/j.pmedr.2022.102086
  • 发表时间:
    2023-03
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Rosal, Milagros C.;Lemon, Stephenie C.;Borg, Amy;Lopez-Cepero, Andrea;Sreedhara, Meera;Silfee, Valerie;Pbert, Lori;Kane, Kevin;Li, Wenjun
  • 通讯作者:
    Li, Wenjun
Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial
  • DOI:
    10.1016/s0140-6736(14)60689-9
  • 发表时间:
    2014-05-24
  • 期刊:
  • 影响因子:
    168.9
  • 作者:
    Brar, Somjot S.;Aharonian, Vicken;Kane, Kevin
  • 通讯作者:
    Kane, Kevin
The effective enforcement of HACCP based food safety management systems in the UK
  • DOI:
    10.1016/j.foodcont.2013.09.016
  • 发表时间:
    2014-03-01
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Green, Russell M.;Kane, Kevin
  • 通讯作者:
    Kane, Kevin
Recipes for neighborhood development: A machine learning approach toward understanding the impact of mixing in neighborhoods
  • DOI:
    10.1016/j.landurbplan.2017.03.006
  • 发表时间:
    2017-08-01
  • 期刊:
  • 影响因子:
    9.1
  • 作者:
    Hipp, John R.;Kane, Kevin;Kim, Jae Hong
  • 通讯作者:
    Kim, Jae Hong

Kane, Kevin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kane, Kevin', 18)}}的其他基金

Determinants of Natural Killer Cell Ly49 Receptor Specificity
自然杀伤细胞 Ly49 受体特异性的决定因素
  • 批准号:
    RGPIN-2016-03744
  • 财政年份:
    2021
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Discovery Grants Program - Individual
Determinants of Natural Killer Cell Ly49 Receptor Specificity
自然杀伤细胞 Ly49 受体特异性的决定因素
  • 批准号:
    RGPIN-2016-03744
  • 财政年份:
    2019
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Discovery Grants Program - Individual
Determinants of Natural Killer Cell Ly49 Receptor Specificity
自然杀伤细胞 Ly49 受体特异性的决定因素
  • 批准号:
    RGPIN-2016-03744
  • 财政年份:
    2018
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Discovery Grants Program - Individual
Determinants of Natural Killer Cell Ly49 Receptor Specificity
自然杀伤细胞 Ly49 受体特异性的决定因素
  • 批准号:
    RGPIN-2016-03744
  • 财政年份:
    2017
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Discovery Grants Program - Individual

相似国自然基金

Natural超对称中的希格斯物理与暗物质研究
  • 批准号:
    11775039
  • 批准年份:
    2017
  • 资助金额:
    52.0 万元
  • 项目类别:
    面上项目
Natural超对称在LHC上的现象学研究
  • 批准号:
    11405015
  • 批准年份:
    2014
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

SBIR Phase I: Endogenously secreted bispecific natural killer cell engagers (BIKEs) for therapy of solid tumors
SBIR I 期:用于治疗实体瘤的内源性分泌双特异性自然杀伤细胞接合剂 (BIKE)
  • 批准号:
    2322959
  • 财政年份:
    2024
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Standard Grant
Human Leukocyte Antigen-A and -B regulation of Natural Killer cell function
人类白细胞抗原 A 和 B 对自然杀伤细胞功能的调节
  • 批准号:
    DP230103117
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Discovery Projects
Targeting aerobic glycolysis via hexokinase 2 inhibition in Natural Killer T cell lymphomas
通过抑制己糖激酶 2 靶向自然杀伤 T 细胞淋巴瘤中的有氧糖酵解
  • 批准号:
    23K07830
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Peptide-Specific Natural Killer Cell Receptors in Health and Disease
健康和疾病中的肽特异性自然杀伤细胞受体
  • 批准号:
    MR/X020746/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Fellowship
Using natural killer cells to prevent breast cancer metastases
使用自然杀伤细胞预防乳腺癌转移
  • 批准号:
    10591362
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
Regulation of natural killer cell-mediated immune response in breast cancer
自然杀伤细胞介导的乳腺癌免疫反应的调节
  • 批准号:
    494926
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Operating Grants
Uncovering the developmental trajectory of Natural Killer cells
揭示自然杀伤细胞的发育轨迹
  • 批准号:
    2898862
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
    Studentship
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
血液系统恶性肿瘤中持续治疗残留肿瘤细胞的自然杀伤细胞耐药机制
  • 批准号:
    10564354
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
The natural killer cell response against mouse cytomegalovirus infection
自然杀伤细胞对小鼠巨细胞病毒感染的反应
  • 批准号:
    10669344
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
Elucidation of Human Natural Killer Cell Development
人类自然杀伤细胞发育的阐明
  • 批准号:
    10587566
  • 财政年份:
    2023
  • 资助金额:
    $ 2.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了